EcoR1 Capital
Latest statistics and disclosures from EcoR1 Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are APLS, ANAB, CRNX, PRTA, JAZZ, and represent 41.32% of EcoR1 Capital's stock portfolio.
- Added to shares of these 10 stocks: JAZZ (+$77M), VRDN (+$45M), MBX (+$31M), IONS (+$20M), RLAY (+$18M), DAWN (+$12M), ANAB (+$9.2M), APLS (+$8.2M), CRNX (+$6.8M), PCVX (+$6.0M).
- Started 14 new stock positions in ARTV, DSGN, ETON, ALLK, RLAY, HOOK, AADI, IONS, DAWN, VRDN. ALGS, MBX, BBIO, MGNX.
- Reduced shares in these 10 stocks: SRPT (-$222M), MORF (-$170M), GLPG (-$161M), CNTA (-$40M), ACAD (-$22M), LENZ (-$21M), ITOS (-$17M), RCKT (-$11M), Hookipa Pharma Inc equity, Aligos Therapeutics.
- Sold out of its positions in ACAD, Aligos Therapeutics, Hookipa Pharma Inc equity, MORF, RCKT, SRPT.
- EcoR1 Capital was a net seller of stock by $-413M.
- EcoR1 Capital has $2.9B in assets under management (AUM), dropping by -10.62%.
- Central Index Key (CIK): 0001587114
Tip: Access up to 7 years of quarterly data
Positions held by EcoR1 Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv

Portfolio Holdings for EcoR1 Capital
EcoR1 Capital holds 63 positions in its portfolio as reported in the September 2024 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Apellis Pharmaceuticals (APLS) | 11.7 | $343M | +2% | 12M | 28.84 |
|
Anaptysbio Inc Common (ANAB) | 8.9 | $261M | +3% | 7.8M | 33.50 |
|
Crinetics Pharmaceuticals In (CRNX) | 7.5 | $219M | +3% | 4.3M | 51.10 |
|
Prothena Corp SHS (PRTA) | 6.6 | $194M | 12M | 16.73 |
|
|
Jazz Pharmaceuticals Shs Usd (JAZZ) | 6.5 | $190M | +68% | 1.7M | 111.41 |
|
Zymeworks Del (ZYME) | 5.8 | $169M | 13M | 12.55 |
|
|
Arvinas Ord (ARVN) | 5.7 | $166M | 6.7M | 24.63 |
|
|
Kura Oncology (KURA) | 3.9 | $114M | 5.8M | 19.54 |
|
|
Xencor (XNCR) | 3.7 | $107M | 5.3M | 20.11 |
|
|
Tango Therapeutics (TNGX) | 3.5 | $103M | 13M | 7.70 |
|
|
Janux Therapeutics (JANX) | 2.3 | $67M | 1.5M | 45.43 |
|
|
Crispr Therapeutics Namen Akt (CRSP) | 2.2 | $65M | 1.4M | 46.98 |
|
|
Immunome (IMNM) | 1.9 | $57M | 3.9M | 14.62 |
|
|
Neurogene (NGNE) | 1.8 | $53M | 1.3M | 41.96 |
|
|
Centessa Pharmaceuticals Sponsored Ads (CNTA) | 1.8 | $52M | -43% | 3.2M | 15.99 |
|
Miragen Therapeutics (VRDN) | 1.5 | $45M | NEW | 2.0M | 22.75 |
|
Nuvation Bio Com Cl A (NUVB) | 1.5 | $44M | 19M | 2.29 |
|
|
Third Harmonic Bio (THRD) | 1.5 | $43M | 3.2M | 13.55 |
|
|
Vaxcyte (PCVX) | 1.4 | $40M | +17% | 353k | 114.27 |
|
Mersana Therapeutics (MRSN) | 1.3 | $37M | 19M | 1.89 |
|
|
Oric Pharmaceuticals (ORIC) | 1.2 | $35M | 3.4M | 10.25 |
|
|
Avidity Biosciences Ord (RNA) | 1.2 | $35M | 758k | 45.93 |
|
|
Edgewise Therapeutics (EWTX) | 1.1 | $33M | 1.3M | 26.69 |
|
|
Mbx Biosciences Com Added (MBX) | 1.0 | $31M | NEW | 1.2M | 25.98 |
|
Neumora Therapeutics (NMRA) | 0.9 | $27M | 2.1M | 13.21 |
|
|
Cargo Therapeutics (CRGX) | 0.9 | $27M | 1.5M | 18.45 |
|
|
Adaptimmune Therapeutics Sponds Adr (ADAP) | 0.9 | $26M | 27M | 0.95 |
|
|
Tectonic Therapeutic (TECX) | 0.9 | $26M | 849k | 30.30 |
|
|
Tscan Therapeutics (TCRX) | 0.9 | $25M | 5.0M | 4.98 |
|
|
Voyager Therapeutics (VYGR) | 0.8 | $23M | 3.9M | 5.85 |
|
|
Celldex Therapeutics Com New (CLDX) | 0.8 | $22M | 650k | 33.99 |
|
|
Bicycle Therapeutics Sponsored Ads (BCYC) | 0.7 | $21M | 910k | 22.63 |
|
|
Ionis Pharmaceuticals (IONS) | 0.7 | $20M | NEW | 500k | 40.06 |
|
Dyne Therapeutics (DYN) | 0.7 | $20M | +30% | 556k | 35.92 |
|
Atea Pharmaceuticals (AVIR) | 0.6 | $18M | 5.4M | 3.35 |
|
|
Relay Therapeutics (RLAY) | 0.6 | $18M | NEW | 2.5M | 7.08 |
|
Pharvaris N V (PHVS) | 0.6 | $17M | 900k | 18.52 |
|
|
Iteos Therapeutics (ITOS) | 0.6 | $16M | -50% | 1.6M | 10.21 |
|
Madrigal Pharmaceuticals (MDGL) | 0.5 | $16M | 75k | 212.22 |
|
|
Day One Biopharmaceuticals I (DAWN) | 0.4 | $12M | NEW | 862k | 13.93 |
|
Keros Therapeutics (KROS) | 0.4 | $11M | 188k | 58.07 |
|
|
Replimune Group (REPL) | 0.3 | $9.3M | 850k | 10.96 |
|
|
Allovir (ALVR) | 0.3 | $9.1M | 11M | 0.81 |
|
|
Lenz Therapeutics (LENZ) | 0.3 | $8.2M | -71% | 347k | 23.74 |
|
Verve Therapeutics (VERV) | 0.2 | $6.1M | 1.3M | 4.84 |
|
|
Generation Bio (GBIO) | 0.2 | $5.1M | 2.0M | 2.47 |
|
|
Eton Pharmaceuticals (ETON) | 0.2 | $4.8M | NEW | 794k | 6.00 |
|
Galapagos Nv Spon Adr (GLPG) | 0.2 | $4.5M | -97% | 155k | 28.79 |
|
Bridgebio Pharma (BBIO) | 0.1 | $4.3M | NEW | 170k | 25.46 |
|
Atara Biotherapeutics Com New (ATRA) | 0.1 | $3.8M | +15% | 469k | 8.13 |
|
Aadi Bioscience (AADI) | 0.1 | $3.8M | NEW | 1.8M | 2.06 |
|
Proqr Thrapeutics N V Shs Euro (PRQR) | 0.1 | $3.3M | -10% | 1.8M | 1.82 |
|
Prime Medicine (PRME) | 0.1 | $2.7M | 700k | 3.87 |
|
|
Hookipa Pharma Com New Added (HOOK) | 0.1 | $2.5M | NEW | 572k | 4.30 |
|
Aligos Therapeutics Com New Added (ALGS) | 0.1 | $2.2M | NEW | 256k | 8.66 |
|
Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.1 | $2.2M | 963k | 2.29 |
|
|
Kyverna Therapeutics (KYTX) | 0.1 | $2.2M | 450k | 4.89 |
|
|
Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $799k | 67k | 11.98 |
|
|
Artiva Biotherapeutics Com Added (ARTV) | 0.0 | $640k | NEW | 42k | 15.45 |
|
Design Therapeutics (DSGN) | 0.0 | $290k | NEW | 54k | 5.38 |
|
Macrogenics (MGNX) | 0.0 | $184k | NEW | 56k | 3.29 |
|
Caremax *w Exp 06/08/202 | 0.0 | $170k | 100k | 1.70 |
|
|
Allakos (ALLK) | 0.0 | $126k | NEW | 192k | 0.65 |
|
Past Filings by EcoR1 Capital
SEC 13F filings are viewable for EcoR1 Capital going back to 2014
- EcoR1 Capital 2024 Q3 filed Nov. 14, 2024
- EcoR1 Capital 2024 Q2 filed Aug. 14, 2024
- EcoR1 Capital 2024 Q1 filed May 15, 2024
- EcoR1 Capital 2023 Q4 filed Feb. 14, 2024
- EcoR1 Capital 2023 Q3 filed Nov. 14, 2023
- EcoR1 Capital 2023 Q2 filed Aug. 14, 2023
- EcoR1 Capital 2023 Q1 filed May 15, 2023
- EcoR1 Capital 2022 Q4 filed Feb. 14, 2023
- EcoR1 Capital 2022 Q3 filed Nov. 14, 2022
- EcoR1 Capital 2022 Q2 filed Aug. 15, 2022
- EcoR1 Capital 2022 Q1 filed May 16, 2022
- EcoR1 Capital 2021 Q4 filed Feb. 14, 2022
- EcoR1 Capital 2021 Q3 restated filed Nov. 22, 2021
- EcoR1 Capital 2021 Q3 filed Nov. 15, 2021
- EcoR1 Capital 2021 Q2 filed Aug. 16, 2021
- EcoR1 Capital 2021 Q1 filed May 17, 2021